Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 18:7:413-422.
doi: 10.2147/JHC.S272762. eCollection 2020.

Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma

Affiliations
Review

Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma

Jingjing Zong et al. J Hepatocell Carcinoma. .

Abstract

Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanced stage or have established distant metastases. The treatment of HCC is limited, with poor prognosis and short natural survival time. In order to improve the efficiency of early diagnosis, it is particularly significant to choose economic and effective diagnosis methods. Ultrasound, magnetic resonance imaging, and computed tomography are usually used in the clinic, but these methods are extremely limited in the diagnosis of HCC. Tumor markers have become the main effective early clinical diagnosis method. Potential serum tumor markers include alpha fetoprotein heterogeneity, Golgi protein 73, phosphatidylinositol proteoglycan (GPC-3), osteopontin, abnormal prothrombin, and heat shock protein. These tumor markers provide new ideas and methods for the diagnosis of HCC. A combination of multiple markers can make up for the deficiency of single marker detection and provide a new strategy for the prognosis and auxiliary diagnosis of HCC. This review introduces protein tumor markers utilized over the past five years.

Keywords: abnormal prothrombin; alpha fetoprotein; heat shock protein; heterogeneous Golgi protein 73; phosphatidylinositol proteoglycan; primary hepatic carcinoma; serum tumor marker; α-fetoprotein.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest for this work.

References

    1. Farber NJ, Kim CJ, Modi PK, Hon JD, Sadimin ET, Singer EA. Renal cell carcinoma: the search for a reliable biomarker. Transl Cancer Res. 2017;6(3):620–632. doi:10.21037/tcr.2017.05.19 - DOI - PMC - PubMed
    1. Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev. 2019;13(1):410. doi:10.4081/oncol.2019.410 - DOI - PMC - PubMed
    1. Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963–2997. - PubMed
    1. Gao J, Song P. Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China: expectation. Drug Discov Ther. 2017;11(3):168–169. doi:10.5582/ddt.2017.01036 - DOI - PubMed
    1. Wang T, Zhang KH, Hu PP, et al. Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. Oncotarget. 2016;7(39):64053–64070. doi:10.18632/oncotarget.11771 - DOI - PMC - PubMed